Xinxin Rao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xinxin Rao has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Bei Li
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, China
2 shared publicationsEnming Tian
Tongji University Cancer Center, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publications- Guido Kroemer
Universitè Paris Citè, Sorbonne Université, Inserm, Centre de Recherche des Cordeliers, Paris, France
2 shared publications Heping Zhang
Tongji University Cancer Center, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publicationsHongmei Zheng
Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications- Oliver Kepp
Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université Paris Cité, Équipe labellisée par la Ligue contre le Cancer, Institut Universitaire de France, Paris, France; INSERM US23/CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France
2 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Springer Nature in Nature Communications
The nucleolar deubiquitinase OTUD4 coordinates spatial organization of perinucleolar heterochromatin to restrain tumor immunogenicity
- 24 October 2026
- Published by Springer Nature in Nature Communications
Open AccessThe nucleolar deubiquitinase OTUD4 coordinates spatial organization of perinucleolar heterochromatin to restrain tumor immunogenicity
- Open Access
- 22 April 2026
- Published by Springer Nature in Research Square
A phosphorylation–deubiquitination circuit drives spatial reorganization of perinucleolar heterochromatin to restrain tumor immunogenicity
Subnuclear compartmentalization has emerged as a critical determinant of transcriptional homeostasis and cell-fate determination. The nucleolus scaffolds specialized heterochromatin, yet the mechanisms orchestrating its spatial assembly and therapeutic relevance remain elusive. Here we identify the nucleolar deubiquitinase OTUD4 as a key coordinator of heterochromatin architecture. We demonstrate that casein kinase II (CK2)-mediated phosphorylation serves as a molecular switch to activate OTUD4, which functions as a phospho-activated, K63-specific deubiquitinase. Crucially, we show that the spatial anchoring of H3K9me3-marked heterochromatin to the nucleolar surface is molecularly mandated by the K63-linked ubiquitination status of Nucleophosmin (NPM1) at the Lys27 (K27) residue. OTUD4-mediated deubiquitination of NPM1 K27 is indispensable for stabilizing the NPM1 pentameric scaffold, which in turn sequesters H3K9me3-marked domains at the nucleolar periphery. Disruption of the CK2–OTUD4–NPM1 axis triggers heterochromatin detachment, eliciting nucleolar stress and retroelement derepression. This epigenetic collapse activates cytosolic DNA-sensing pathways to potentiate tumor-intrinsic immunogenicity. Clinically, an OTUD4-nucleolus gene signature correlates with adverse survival and immunotherapy resistance. Together, these findings establish a phosphorylation–deubiquitination cascade to preserve heterochromatin topology and nominate spatial epigenetic targeting as a translational strategy to overcome immune evasion in refractory malignancies.
- 22 April 2026
- Published by Springer Nature in Research Square
Open AccessA phosphorylation–deubiquitination circuit drives spatial reorganization of perinucleolar heterochromatin to restrain tumor immunogenicity
Subnuclear compartmentalization has emerged as a critical determinant of transcriptional homeostasis and cell-fate determination. The nucleolus scaffolds specialized heterochromatin, yet the mechanisms orchestrating its spatial assembly and therapeutic relevance remain elusive. Here we identify the nucleolar deubiquitinase OTUD4 as a key coordinator of heterochromatin architecture. We demonstrate that casein kinase II (CK2)-mediated phosphorylation serves as a molecular switch to activate OTUD4, which functions as a phospho-activated, K63-specific deubiquitinase. Crucially, we show that the spatial anchoring of H3K9me3-marked heterochromatin to the nucleolar surface is molecularly mandated by the K63-linked ubiquitination status of Nucleophosmin (NPM1) at the Lys27 (K27) residue. OTUD4-mediated deubiquitination of NPM1 K27 is indispensable for stabilizing the NPM1 pentameric scaffold, which in turn sequesters H3K9me3-marked domains at the nucleolar periphery. Disruption of the CK2–OTUD4–NPM1 axis triggers heterochromatin detachment, eliciting nucleolar stress and retroelement derepression. This epigenetic collapse activates cytosolic DNA-sensing pathways to potentiate tumor-intrinsic immunogenicity. Clinically, an OTUD4-nucleolus gene signature correlates with adverse survival and immunotherapy resistance. Together, these findings establish a phosphorylation–deubiquitination cascade to preserve heterochromatin topology and nominate spatial epigenetic targeting as a translational strategy to overcome immune evasion in refractory malignancies.
- Open Access
- 7 August 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (8) , e1787
Integrating radiosensitivity index and triple‐negative breast cancer subtypes reveals SERPINB5 as a radioresistance biomarker in triple‐negative breast cancer
- 7 August 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (8) , e1787
Open AccessIntegrating radiosensitivity index and triple‐negative breast cancer subtypes reveals SERPINB5 as a radioresistance biomarker in triple‐negative breast cancer
- Open Access
- 8 February 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (2) , 225
Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening
Triple-negative breast cancer (TNBC) poses a therapeutic challenge due to its aggressive nature and lack of targeted therapies. Epigenetic modifications contribute to TNBC tumorigenesis and drug resistance, offering potential therapeutic targets. Recent advancements in three-dimensional (3D) organoid cultures, enabling precise drug screening, hold immense promise for identifying novel compounds targeting TNBC. In this study, we established two patient-derived TNBC organoids and implemented a high-throughput drug screening system using these organoids and two TNBC cell lines. Screening a library of 169 epigenetic compounds, we found that organoid-based systems offer remarkable precision in drug response assessment compared to cell-based models. The top 30 compounds showing the highest drug sensitivity in the initial screening were further assessed in a secondary screen. Four compounds, panobinostat, pacritinib, TAK-901, and JIB-04, targeting histone deacetylase, JAK/STAT, histone demethylases, and aurora kinase pathways, respectively, exhibited potent anti-tumor activity in TNBC organoids, surpassing the effect of paclitaxel. Our study highlights the potential of these novel epigenetic drugs as effective therapeutic agents for TNBC and demonstrates the valuable role of patient-derived organoids in advancing drug discovery.
- 8 February 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (2) , 225
Open AccessUnveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening
Triple-negative breast cancer (TNBC) poses a therapeutic challenge due to its aggressive nature and lack of targeted therapies. Epigenetic modifications contribute to TNBC tumorigenesis and drug resistance, offering potential therapeutic targets. Recent advancements in three-dimensional (3D) organoid cultures, enabling precise drug screening, hold immense promise for identifying novel compounds targeting TNBC. In this study, we established two patient-derived TNBC organoids and implemented a high-throughput drug screening system using these organoids and two TNBC cell lines. Screening a library of 169 epigenetic compounds, we found that organoid-based systems offer remarkable precision in drug response assessment compared to cell-based models. The top 30 compounds showing the highest drug sensitivity in the initial screening were further assessed in a secondary screen. Four compounds, panobinostat, pacritinib, TAK-901, and JIB-04, targeting histone deacetylase, JAK/STAT, histone demethylases, and aurora kinase pathways, respectively, exhibited potent anti-tumor activity in TNBC organoids, surpassing the effect of paclitaxel. Our study highlights the potential of these novel epigenetic drugs as effective therapeutic agents for TNBC and demonstrates the valuable role of patient-derived organoids in advancing drug discovery.